newsfilter
← Latest News
GlobeNewswire·

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy